MiR-424 Functions as Potential Diagnostic and Prognostic Biomarker in Melanoma

Xu, Shengjing; Xu, Wenjing; Zeng, Zhi; Zhang, Min; Zhang, Dongyan

doi:10.7754/clin.lab.2019.190917

Cited by 11 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irrelevant articles, reviews, abstracts, and case reports were excluded by screening the titles and abstracts, and thereby excluding 621 articles. Further, 25 articles were fully read and evaluated, 10 of which were excluded because there did not contain enough available diagnostic data, [ 22 , 26 , 27 , 30 , 32 , 40 – 44 ] another 2 were excluded because they were reviews, [ 45 , 46 ] and 3 were excluded because they did not discuss circulating miRNAs [ 33 , 47 , 48 ]. Finally, a total of 16 studies from 10 publications met the inclusion criteria and were included in this meta-analysis (Fig.…”

Section: Resultsmentioning

confidence: 99%

Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis

Sun

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background Recent studies have shown that circulating microRNAs (miRNAs) can be used as diagnostic biomarkers for melanoma. This study aimed to evaluate the diagnostic value of circulating miRNAs for melanoma. Methods A comprehensive literature search was conducted and the quality of the included literature was evaluated using QUADAS-2 (Quality Assessment for diagnostic accuracy studies), and the diagnostic accuracy was assessed by pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC). We used Deeks’ funnel plot to evaluate publication bias. Results The meta-analysis included 10 articles covering 16 studies, and the results showed that circulating miRNAs provide high diagnostic accuracy for melanoma. The overall pooled sensitivity was 0.87 (95% CI: 0.82–0.91), specificity was 0.81 (95% CI: 0.77–0.85), PLR was 4.6 (95% CI: 3.7–5.8), NLR was 0.16 (95% CI: 0.11–0.23), DOR was 29 (95% CI: 18–49), and AUC was 0.90 (95% CI: 0.87–0.92), respectively. Subgroup analysis showed better diagnostic value in miRNA clusters, European population, plasma miRNAs, and upregulated miRNAs compared to other subgroups. Conclusions The results indicated that circulating microRNAs can be used as a non-invasive biomarker for the diagnosis of melanoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis

Sun

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

show abstract

“… 16 , 21 It has been reported that miR-424 serves as the potential biomarker for the diagnosis and prognosis in melanoma. 36 MiR-410-3p stimulated by vemurafenib by ER stress contributes to the BRAF inhibitor resistance in melanoma. 21 MiR-33a-5p represses the metastasis and growth of melanoma cells by modulating the expression of SNAI2.…”

Section: Discussionmentioning

confidence: 99%

Bergamottin Induces DNA Damage and Inhibits Malignant Progression in Melanoma by Modulating miR-145/Cyclin D1 Axis

Zhao¹,

Liao²

2021

OTT

View full text Add to dashboard Cite

Background Melanoma is a prevalent skin cancer with the high rate of metastasis and mortality, affecting the increasing number of people worldwide. Bergamottin (BGM) is a natural furanocoumarin derived from grapefruits and presents the potential anti-cancer activity in several tumor models. However, the role of BGM in the development of melanoma remains unclear. Here, we aimed to explore the effect of BGM on the DNA damage and progression of melanoma. Methods The effect of BGM on the melanoma progression was analyzed by CCK-8 assays, colony formation assays, transwell assays, Annexin V-FITC Apoptosis Detection Kit, cell-cycle analysis, in vivo tumorigenicity analysis. The mechanism investigation was performed using luciferase reporter gene assays, qPCR assays, and Western blot analysis. Results We identified that BGM repressed cell proliferation, migration, and invasion of melanoma cells. BGM induced cell cycle arrest at the G0/G1 phase and enhanced apoptosis of melanoma cells. The DNA damage in the melanoma cells was stimulated by the BGM treatment. Meanwhile, BGM was able to up-regulate the expression of miR-145 and miR-145 targeted Cyclin D1 in the melanoma cells. Furthermore, BGM inhibited the progression of melanoma by targeting miR-145/Cyclin D1 axis in vitro. BGM attenuated the tumor growth of melanoma in vivo. Conclusion Thus, we conclude that BGM induces DNA damage and inhibits tumor progression in melanoma by modulating the miR-145/Cyclin D1 axis. Our finding provides new insights into the mechanism by which BGM modulates the development of melanoma. BGM may be applied as a potential anti-tumor candidate for the clinical treatment of melanoma.

show abstract

“…The aim of Xu et al’s [ 69 ] study was to determine the clinical value of miR-424 in melanoma. They demonstrated that the expression of miR-424 remarkably increased in tissues and serum of patients with melanoma.…”

Section: Examples Of Melanoma-related Micrornasmentioning

confidence: 99%

MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection—Narrative Review

Poniewierska-Baran

Zadroga

Danilyan

et al. 2023

IJMS

View full text Add to dashboard Cite

Melanoma is the most serious type of skin cancer, causing a large majority of deaths but accounting for only ~1% of all skin cancer cases. The worldwide incidence of malignant melanoma is increasing, causing a serious socio-economic problem. Melanoma is diagnosed mainly in young and middle-aged people, which distinguishes it from other solid tumors detected mainly in mature people. The early detection of cutaneous malignant melanoma (CMM) remains a priority and it is a key factor limiting mortality. Doctors and scientists around the world want to improve the quality of diagnosis and treatment, and are constantly looking for new, promising opportunities, including the use of microRNAs (miRNAs), to fight melanoma cancer. This article reviews miRNA as a potential biomarker and diagnostics tool as a therapeutic drugs in CMM treatment. We also present a review of the current clinical trials being carried out worldwide, in which miRNAs are a target for melanoma treatment.

show abstract

MiR-424 Functions as Potential Diagnostic and Prognostic Biomarker in Melanoma

Cited by 11 publications

References 0 publications

Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis

Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis

Bergamottin Induces DNA Damage and Inhibits Malignant Progression in Melanoma by Modulating miR-145/Cyclin D1 Axis

MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection—Narrative Review

Contact Info

Product

Resources

About